Error in Discussion

In the Original Investigation titled “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial,”¹ published January 13, 2021, there were errors in the Discussion section. The penultimate sentence of the first paragraph should have referred to a 0.8% weight loss among patients receiving placebo. The final sentence should have read that weight loss with bimagrumab was greater than the 1-year FDA threshold of 5% for registration of new medicines for treating obesity and overweight. This article has been corrected.¹